Valuation: AstraZeneca PLC

Market Cap 261B 233B 216B 197B 370B 24,806B 377B 2,592B 1,015B 12,900B 979B 959B 41,262B P/E 2026 *
22x
P/E 2027 * 18.9x
Enterprise Value 281B 251B 232B 212B 399B 26,701B 406B 2,790B 1,093B 13,886B 1,054B 1,032B 44,415B EV / Sales 2026 *
4.43x
EV / Sales 2027 * 4.06x
Free-Float
96.62%
Yield 2026 *
1.99%
Yield 2027 * 2.11%
1 day+2.87%
Current month+79.67%
Current year+81.31%
Current year 89.04
Extreme 89.04
169.81
1 year 80.48
Extreme 80.48
169.81
3 years 60.47
Extreme 60.47
169.81
5 years 52.65
Extreme 52.65
169.81
10 years 25.55
Extreme 25.55
169.81
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Chief Operating Officer 55 2015-05-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
+2.87%+1.19% - - 251B
+3.55%+5.29%+54.07%+105.45% 1,077B
-0.25%-2.00%+32.71%+61.48% 612B
+0.59%+4.44%+23.69%+91.54% 501B
-1.48%+1.68%+71.42%+39.59% 364B
+2.37%+5.47%+32.67%+48.87% 353B
+2.64%+4.90%+21.01%+43.85% 278B
+3.24%+4.25%-0.31%+15.71% 251B
+1.86%+5.07%+47.70%+52.77% 230B
+2.49%+7.16%+32.82%+102.67% 190B
Average +1.84%+1.97%+35.09%+62.44% 428.5B
Weighted average by Cap. +1.36%+1.58%+39.06%+71.72%

Financials

2026 *2027 *
Net sales 63.4B 56.54B 52.45B 47.77B 89.97B 6,026B 91.59B 630B 247B 3,134B 238B 233B 10,023B 67.37B 60.08B 55.73B 50.76B 95.6B 6,403B 97.32B 669B 262B 3,330B 253B 247B 10,651B
Net income 11.81B 10.53B 9.77B 8.9B 16.75B 1,122B 17.05B 117B 45.92B 584B 44.29B 43.36B 1,866B 13.73B 12.24B 11.36B 10.34B 19.48B 1,305B 19.83B 136B 53.4B 679B 51.51B 50.42B 2,171B
Net Debt 19.94B 17.78B 16.5B 15.03B 28.3B 1,895B 28.81B 198B 77.57B 986B 74.81B 73.24B 3,153B 12.31B 10.97B 10.18B 9.27B 17.46B 1,170B 17.78B 122B 47.86B 608B 46.16B 45.19B 1,945B
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
26-10-15 $166.68 +2.87% 4,227,415
26-10-14 $162.03 +3.99% 3,333,925
26-10-13 $155.82 -1.59% 3,112,422
26-10-12 $158.33 -0.55% 2,855,694
26-10-09 $159.20 +0.26% 2,121,775
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
168.27USD
Average target price
208.95USD
Spread / Average Target
+24.17%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AstraZeneca PLC